Healthcare provider profile · identity verified

William Michael Ellerbe, M.D.

Family Practice · COVINGTON, LA · NPI 1174733489

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	514	154
Amlodipine Besylate	Amlodipine Besylate	369	113
Levothyroxine Sodium	Levothyroxine Sodium	341	100
Losartan Potassium	Losartan Potassium	263	82
Pantoprazole Sodium	Pantoprazole Sodium	240	75
Alprazolam	Alprazolam	228	30
Lisinopril	Lisinopril	223	64
Metoprolol Succinate	Metoprolol Succinate	210	62
Omeprazole	Omeprazole	207	62
Gabapentin	Gabapentin	199	72
Hydrochlorothiazide	Hydrochlorothiazide	191	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	158	38
Metformin Hcl	Metformin Hcl	146	40
Pravastatin Sodium	Pravastatin Sodium	145	46
Sertraline Hcl	Sertraline Hcl	144	43
Rosuvastatin Calcium	Rosuvastatin Calcium	143	48
Tamsulosin Hcl	Tamsulosin Hcl	143	43
Clopidogrel	Clopidogrel Bisulfate	132	38
Simvastatin	Simvastatin	128	34
Montelukast Sodium	Montelukast Sodium	126	37
Potassium Chloride	Potassium Chloride	118	36
Zolpidem Tartrate	Zolpidem Tartrate	108	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	102	42
Eliquis	Apixaban	95	22
Mounjaro	Tirzepatide	95	15
Alendronate Sodium	Alendronate Sodium	94	33
Duloxetine Hcl	Duloxetine Hcl	94	25
Escitalopram Oxalate	Escitalopram Oxalate	94	29
Fluticasone Propionate	Fluticasone Propionate	94	48
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	93	26
Furosemide	Furosemide	91	32
Trazodone Hcl	Trazodone Hcl	88	32
Metformin Hcl Er	Metformin Hcl	82	25
Lorazepam	Lorazepam	81	12
Tramadol Hcl	Tramadol Hcl	79	23
Albuterol Sulfate Hfa	Albuterol Sulfate	78	31
Ozempic	Semaglutide	69	18
Valsartan	Valsartan	69	19
Allopurinol	Allopurinol	66	23
Meloxicam	Meloxicam	63	22
Diazepam	Diazepam	60	suppressed
Diclofenac Sodium	Diclofenac Sodium	60	26
Famotidine	Famotidine	57	22
Clonazepam	Clonazepam	56	11
Citalopram Hbr	Citalopram Hydrobromide	54	17
Glimepiride	Glimepiride	52	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	51	15
Carvedilol	Carvedilol	50	17
Fenofibrate	Fenofibrate	49	15
Atenolol	Atenolol	48	13
Hydroxyzine Hcl	Hydroxyzine Hcl	46	16
Metoprolol Tartrate	Metoprolol Tartrate	46	18
Fluoxetine Hcl	Fluoxetine Hcl	45	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	43	27
Pregabalin	Pregabalin	42	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	12
Esomeprazole Magnesium	Esomeprazole Magnesium	38	13
Olmesartan Medoxomil	Olmesartan Medoxomil	38	11
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	35	13
Topiramate	Topiramate	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	33	11
Temazepam	Temazepam	33	suppressed
Glipizide Er	Glipizide	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Hydralazine Hcl	Hydralazine Hcl	31	suppressed
Benazepril Hcl	Benazepril Hcl	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Lovastatin	Lovastatin	30	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Nystatin	Nystatin	30	suppressed
Ketoconazole	Ketoconazole	29	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	28	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Azelastine Hcl	Azelastine Hcl	27	16
Clotrimazole	Clotrimazole	26	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	25	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Mupirocin	Mupirocin	25	16
Bupropion Hcl	Bupropion Hcl	24	suppressed
Finasteride	Finasteride	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Linzess	Linaclotide	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Methocarbamol	Methocarbamol	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	14
Glipizide	Glipizide	23	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	23	suppressed
Irbesartan	Irbesartan	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Ramipril	Ramipril	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Ondansetron Odt	Ondansetron	18	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Estradiol	Estradiol	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Methylprednisolone	Methylprednisolone	16	16
Bupropion Xl	Bupropion Hcl	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Ibuprofen	Ibuprofen	14	12
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Dutasteride	Dutasteride	13	suppressed
Fluconazole	Fluconazole	13	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error